OncoZenge
5,36
SEK
Mindre end 1K følgere
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
+6,56%
+19,78%
-14,1%
+42,93%
+25,97%
+53,14%
+85,15%
-
-56,2%
OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.
Læs mereMarkedsværdi
62,78 mio. SEK
Aktieomsætning
-
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
21.8
2025
Delårsrapport Q2'25
20.11
2025
Delårsrapport Q3'25
Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Redeye: OncoZenge Q1 - Pieces falling into place
OncoZenge AB: OncoZenge: Investor Receives NDRC Approval
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools